

plasma testosterone levels in hypogonadal individuals treated with AndroGel, impact of showering shortly after application

Published: 12-11-2008

Last updated: 06-05-2024

to investigate whether showering shortly after Androgel application adversely affects plasma testosterone levels.

Ethical review	Approved WMO
Status	Recruiting
Health condition type	Endocrine disorders of gonadal function
Study type	Interventional

Summary

ID

NL-OMON32664

Source

ToetsingOnline

Brief title

androgel shower study

Condition

- Endocrine disorders of gonadal function

Synonym

hypogonadism

Research involving

Human

Sponsors and support

Primary sponsor: Vrije Universiteit Medisch Centrum

Source(s) of monetary or material Support: Goodlife Healthcare bv

Intervention

Keyword: gel, testosterone, transfer

Outcome measures

Primary outcome

maximal testosterone level

area under the curve

time average concentration

Secondary outcome

na

Study description

Background summary

AndroGel (transdermal testosterone) is the most used mode of androgen supplementation in the Netherlands. A potential drawback associated with the use of this gel is the potential of involuntary testosterone transfer to women and children. Taking a shower after application of the gel prevents significant transfer, however it may potentially diminish testosterone uptake by the skin.

Study objective

to investigate whether showering shortly after AndroGel application adversely affects plasma testosterone levels.

Study design

prospective, randomized, cross-over

Intervention

during three weeks AndroGel 50 mg in three regimes of one week

- application after showering

- application 15 minutes before showering

- application 30 minutes before showering

Study burden and risks

the use of Androgel 50 mg (very low risk, low burden)
on three days, at the end of every study week at 5 time points blood is drawn
(7 ml; 15 blood tests in total) at 08:00 h, 09:00 h, 12:00 h, 16:00h, 18:00h
(low risk, moderate burden)

Contacts

Public

Vrije Universiteit Medisch Centrum

postbus 7057

1007 mb

Nederland

Scientific

Vrije Universiteit Medisch Centrum

postbus 7057

1007 mb

Nederland

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

female-to male transsexual after gonadectomy
age 18-60 years

Exclusion criteria

known intolerance for a Androgel
chronic skin condition

Study design

Design

Study phase:	4
Study type:	Interventional
Intervention model:	Crossover
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL	
Recruitment status:	Recruiting
Start date (anticipated):	01-01-2009
Enrollment:	10
Type:	Actual

Ethics review

Approved WMO	
Date:	12-11-2008
Application type:	First submission
Review commission:	METC Amsterdam UMC

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL24711.029.08